{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-002125","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.612409+00:00","generated_at":"2026-06-20T11:36:19.379542+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harrow closes $130M acquisition of five branded ophthalmic products from Novartis","bullets":["Paid $130M at closing for U.S. rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, TRIESENCE; up to $45M milestone for Triesence.","Funded with $59.75M senior secured loan, stock sale ($22.6M net), $40.25M 11.875% notes due 2027, and cash.","Expects ~6-month transition; Novartis continues selling, transfers net profit to Harrow; NDAs to transfer.","Reaffirms 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M; expects growth in 2024 and beyond.","Products expected immediately accretive."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-002125","json":"https://secwatch.observer/filing/0001493152-23-002125.json","markdown":"https://secwatch.observer/filing/0001493152-23-002125.md","text":"https://secwatch.observer/filing/0001493152-23-002125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/0001493152-23-002125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:36:19.379542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5752fb9a7f62351fbe5095b240f7bc94617d906b","claim":"HARROW, INC. completed an acquisition involving Novartis Technology, LLC and Novartis Innovative Therapies AG for $130,000,000 (closed 2023-01-20).","evidence_excerpt":"suspension) 40 mg/ml. Under the terms of the Asset Purchase Agreement between the Company and Novartis (the “Purchase Agreement”), the Company made a one-time payment of $130,000,000 at closing, with up to another $45,000,000 due in a milestone payment related to the commercial availability of Triesence. Pursuant to the Purchase Agreement and various ancillary","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/0001493152-23-002125-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Novartis Technology, LLC and Novartis Innovative Therapies AG"},{"label":"Consideration","value":"$130,000,000"},{"label":"Closing","value":"2023-01-20"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}